Salveen Richter, Goldman Sachs lead US biotech analyst for global investment research, joins Market Domination with Josh ...

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research ...

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a price target of $9, down from $12, ...

O n Wednesday, Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at ...

What Else: Goldman Sachs analyst Salveen Richter recently downgraded Moderna from Buy to Neutral and lowered the price target from $99 to $51, citing lower conviction following a second product ...

Goldman Sachs analyst Salveen Richter notes that Biogen’s management expects to remain disciplined with regard to capital allocation, pointing to an interest in early-to-mid-stage deals in ...

The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative direction, according to Goldman analyst Salveen Richter. Consequently ...

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Good day, and thank you for standing by. Welcome to the Moderna fourth quarter 2024 conference call. (Operator Instructions) Please be advised ...

The company ended the year with $11.2 billion in cash and investments. Salveen Richter, Goldman Sachs: Questioned retail pharmacy and P&T committee pre-launch efforts for JOURNAVX. COO Stuart ...

Salveen Richter, Goldman Sachs: Inquired about BLU-808’s safety profile and potential dosing strategies. CMO Becker Hewes noted the drug’s wide therapeutic index and plans to test various ...

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Good day, and thank you for standing by. Welcome to the Moderna fourth quarter 2024 conference call. (Operator Instructions) Please be advised, ...

Bernstein & Co. Salveen Richter; Analyst; Goldman Sachs Group, Inc. David Amsellem; Analyst; Piper Sandler & Co. Thank you, Julianne. Good afternoon, everyone, and welcome to our fourth quarter 2024 ...